Literature DB >> 8931636

The enteroinsular axis in dipeptidyl peptidase IV-negative rats.

R A Pederson1, T J Kieffer, R Pauly, H Kofod, J Kwong, C H McIntosh.   

Abstract

Evidence has accumulated that the incretins glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1(7-36) amide) are degraded and rendered biologically inactive in plasma by the enzyme dipeptidyl peptidase IV (DPIV). A strain of Fischer rats lacking the DPIV enzyme were used in the current investigation as a model for examining the enteroinsular axis under conditions in which normal inactivation of GIP and GLP-1(7-36) does not occur. This was assessed by comparing GIP and GLP-1(7-36) responses following oral glucose in normal versus DPIV-deficient Fischer rats, and by comparing the insulinotropic potency of both peptides in the perfused pancreas of both groups. The insulin response to an oral glucose challenge was decreased slightly in DPIV-negative rats compared with control animals. Of the two incretins, the GIP response to oral glucose was reduced by 50% compared with controls, whereas GLP-1(7-36) release in response to glucose was unchanged. A decrease of 30% in the sensitivity of the perfused pancreas of DPIV-negative rats to GIP was observed, whereas the insulin response to GLP(7-36) was identical in both groups. Incubation of both peptides in plasma from DPIV-positive and -negative rats was performed to determine the effect of the presence or absence of DPIV on the insulinotropic activity of GLP-1(7-36) and GIP in the isolated perfused rat pancreas. Incubation in plasma from DPIV-positive rats resulted in a 65% decrease in insulinotropic activity of both incretins compared with incubation in plasma from DPIV-deficient rats. It was hypothesized that the reduced GIP response and decreased sensitivity of the pancreas to GIP are compensatory mechanisms that maintain insulin and glucose levels within a normal range despite abnormal degradation of GIP. An explanation of the lack of effect of the absence of DPIV on the GLP-1(7-36) response to oral glucose and insulinotropic action of this peptide must await further study.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8931636     DOI: 10.1016/s0026-0495(96)90112-2

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  7 in total

1.  Glucose-dependent insulinotropic polypeptide stimulates the proliferation of colorectal cancer cells.

Authors:  Daniel Prabakaran; Baogui Wang; Joseph D Feuerstein; Jennifer A Sinclair; Priti Bijpuria; Lisa I Jepeal; M Michael Wolfe
Journal:  Regul Pept       Date:  2010-04-28

2.  The therapeutic actions of DPP-IV inhibition are not mediated by glucagon-like peptide-1.

Authors:  M A Nauck; A El-Ouaghlidi
Journal:  Diabetologia       Date:  2005-03-11       Impact factor: 10.122

3.  Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26.

Authors:  D Marguet; L Baggio; T Kobayashi; A M Bernard; M Pierres; P F Nielsen; U Ribel; T Watanabe; D J Drucker; N Wagtmann
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

4.  Effects of dipeptidyl peptidase IV on the satiety actions of peptide YY.

Authors:  S Unniappan; C H S McIntosh; H-U Demuth; U Heiser; R Wolf; T J Kieffer
Journal:  Diabetologia       Date:  2006-06-27       Impact factor: 10.122

5.  Transgenic rescue of adipocyte glucose-dependent insulinotropic polypeptide receptor expression restores high fat diet-induced body weight gain.

Authors:  Randi Ugleholdt; Jens Pedersen; Maria Rosaria Bassi; Ernst-Martin Füchtbauer; Signe Marie Jørgensen; Hanne-Louise Kissow; Nikolaj Nytofte; Steen Seier Poulsen; Mette Marie Rosenkilde; Yutaka Seino; Peter Thams; Peter Johannes Holst; Jens Juul Holst
Journal:  J Biol Chem       Date:  2011-10-25       Impact factor: 5.157

Review 6.  Unravelling the immunological roles of dipeptidyl peptidase 4 (DPP4) activity and/or structure homologue (DASH) proteins.

Authors:  L Wagner; C Klemann; M Stephan; S von Hörsten
Journal:  Clin Exp Immunol       Date:  2016-03-02       Impact factor: 4.330

Review 7.  Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors.

Authors:  Erin E Mulvihill; Daniel J Drucker
Journal:  Endocr Rev       Date:  2014-09-12       Impact factor: 19.871

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.